BullishAgent BullishAgent Filings Market Economic Earnings Ratings Gaps IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

CSTL

Castle Biosciences, Inc. NASDAQ Listed Jul 25, 2019
Healthcare ·Medical - Diagnostics & Research ·US · castlebiosciences.com
$19.24
Pre-mkt $19.95 +0.61%
Mkt Cap $582.9M
52w Low $14.59 15.7% of range 52w High $44.28
50d MA $25.54 200d MA $28.54
P/E (TTM) -29.9x
EV/EBITDA 92.4x
P/B 1.5x
Debt/Equity 0.1x
ROE -5.1%
P/FCF 39.8x
RSI (14)
ATR (14)
Beta 1.19
50d MA $25.54
200d MA $28.54
Avg Volume 375.4K
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
SIC Code
8071
CIK (SEC)
Phone
866 788 9007
505 South Friendswood Drive · Friendswood, TX 77546 · US
Data updated apr 25, 2026 3:35am · Source: massive.com